Analysts Set Medpace Holdings, Inc. (NASDAQ:MEDP) Target Price at $487.36

Medpace Holdings, Inc. (NASDAQ:MEDP) has earned a consensus rating of “Hold” from the fourteen research firms that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $483.4545.

A number of equities analysts recently weighed in on the stock. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective on the stock in a research report on Friday, February 13th. Leerink Partners lowered their target price on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. BMO Capital Markets reissued a “market perform” rating on shares of Medpace in a report on Wednesday, February 11th. Barclays dropped their target price on Medpace from $525.00 to $500.00 and set an “underweight” rating on the stock in a research report on Wednesday, February 11th. Finally, Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th.

Insider Buying and Selling at Medpace

In other news, CEO August J. Troendle sold 42,392 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $615.52, for a total value of $26,093,123.84. Following the completion of the transaction, the chief executive officer owned 732,210 shares in the company, valued at $450,689,899.20. This trade represents a 5.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have sold 122,720 shares of company stock worth $74,312,523. Corporate insiders own 20.30% of the company’s stock.

Institutional Investors Weigh In On Medpace

Several institutional investors have recently modified their holdings of the company. Clarkston Capital Partners LLC bought a new position in Medpace during the 2nd quarter valued at $40,569,000. Cibc World Market Inc. acquired a new position in Medpace in the third quarter worth about $5,033,000. Brighton Jones LLC increased its holdings in Medpace by 160.4% in the third quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock valued at $2,087,000 after buying an additional 2,501 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in Medpace by 150.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock valued at $8,080,000 after buying an additional 9,117 shares in the last quarter. Finally, Baillie Gifford & Co. lifted its holdings in Medpace by 12.0% during the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after buying an additional 62,503 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

NASDAQ MEDP opened at $453.77 on Monday. Medpace has a one year low of $250.05 and a one year high of $628.92. The firm has a market cap of $12.88 billion, a PE ratio of 29.66, a P/E/G ratio of 2.17 and a beta of 1.42. The firm’s fifty day moving average is $556.01 and its two-hundred day moving average is $539.44.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The firm had revenue of $708.45 million for the quarter, compared to analysts’ expectations of $689.53 million. During the same quarter in the previous year, the firm posted $3.67 EPS. The firm’s revenue for the quarter was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts predict that Medpace will post 12.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.